NCT00161668View on ClinicalTrials.gov

Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

CompletedOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

October 31, 2001

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Mylotarg

Trial Locations (59)

10019

New York

10032

New York

10466

The Bronx

10595

Valhalla

11040

New Hyde Park

14263

Buffalo

15224

Pittsburgh

19104

Philadelphia

19107

Philadelphia

22205

Arlington

25304

Charleston

27106

Winston-Salem

27705

Durham

33321

Tamarac

33324

Plantation

33435

Boynton Beach

34994

Stuart

37205

Nashville

38120

Memphis

40202

Louisville

44195

Cleveland

44302

Akron

44718

Canton

45236

Cincinnati

46202

Indianapolis

49048

Kalamazoo

49503

Grand Rapids

52242

Iowa City

54911

Appleton

58501

Bismarck

60611

Chicago

60637

Chicago

63141

St Louis

65203

Columbia

72112

Oklahoma City

76508

Temple

77030

Houston

80218

Denver

85404

Tucson

87109

Albuquerque

91342

Sylmar

91505

Burbank

92354

Loma Linda

94143

San Francisco

94520

Concord

94704

Berkely

97201

Portland

90095-1678

Los Angeles

60612-3838

Chicago

60612-7323

Chicago

40536-0093

Lexington

71130-3932

Shrevport

48109-0999

Ann Arbor

49007-3731

Kalamazoo

07754

Neptune City

17033-0850

Hershey

37232-5505

Nashville

23298-0157

Richmond

26506-9162

Morgantown

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00161668 - Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care | Biotech Hunter | Biotech Hunter